Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902

Daniel A. Hamstra, Stephanie L. Pugh, Herbert Lepor, Seth A. Rosenthal, Kenneth Pienta, Leonard Gomella, Christopher Peters, David Paul D'Souza, Kenneth L. Zeitzer, Christopher U. Jones, William A. Hall, Eric Horwitz, Thomas M. Pisansky, Luis Souhami, Alan C. Hartford, Michael Dominello, Felix Feng, Howard M. Sandler

Research output: Contribution to journalArticle

Abstract

Background/purpose: Stratification of Gleason score (GS) into three categories (2–6, 7, and 8–10) may not fully utilize its prognostic discrimination, with Gleason pattern 5 (GP5) previously identified as an independent adverse factor. Materials/methods: Patients treated on RTOG 9202 (n = 1292) or RTOG 9902 (n = 378) were pooled and assessed for association of GS and GP5 on biochemical failure (BF), local failure (LF), distant metastasis (DM), and overall survival (OS). Fine and Gray's regression and cumulative incidence methods were used for univariate and multivariate analyses. Results: With median follow-up of 9.4 years, patients with GS 8–10 with GP5 had worse outcome than GS 4 + 4 for DM on both RTOG9202 (p = 0.038) and RTOG9902 (p < 0.001) with a trend toward worse OS (p = 0.059 and p = 0.089, respectively), but without differences in BF or LF. At 10-years DM was higher by 11% (RTOG 9202) and 18% (RTOG 9902) with GP5 compared to GS 4 + 4. On multivariate analysis restricted to long-term androgen deprivation therapy the presence of GP5 substantially increased distant metastasis (HR = 0.43, 95%CI: 0.24–0.76, p = 0.0039) with a trend toward worse OS (HR:0.74, 95% CI:0.54–1.0, p = 0.052) without association with LF (HR:0.55, 95%CI:0.28–1.09, p = 0.085) or BF (HR:1.15, 95%CI:0.84–1.59, p = 0.39). We did not observed substantial differences between Gleason 3 + 5, 5 + 3, or Gleason 9–10. Conclusions: These results validate GP5 as an independent prognostic factor which is strongest for DM. As a result GP5 should be considered when stratifying patients with GS 8 and may be a patient population in which to evaluate newly approved systemic therapies or additional local treatments.

Original languageEnglish (US)
JournalRadiotherapy and Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Neoplasm Grading
Androgens
Radiotherapy
Neoplasm Metastasis
Survival
Multivariate Analysis
Therapeutics
Incidence
Population

Keywords

  • Distant metastasis
  • Gleason score
  • Prostate cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation : An analysis of RTOG 9202 and 9902. / Hamstra, Daniel A.; Pugh, Stephanie L.; Lepor, Herbert; Rosenthal, Seth A.; Pienta, Kenneth; Gomella, Leonard; Peters, Christopher; D'Souza, David Paul; Zeitzer, Kenneth L.; Jones, Christopher U.; Hall, William A.; Horwitz, Eric; Pisansky, Thomas M.; Souhami, Luis; Hartford, Alan C.; Dominello, Michael; Feng, Felix; Sandler, Howard M.

In: Radiotherapy and Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Hamstra, DA, Pugh, SL, Lepor, H, Rosenthal, SA, Pienta, K, Gomella, L, Peters, C, D'Souza, DP, Zeitzer, KL, Jones, CU, Hall, WA, Horwitz, E, Pisansky, TM, Souhami, L, Hartford, AC, Dominello, M, Feng, F & Sandler, HM 2019, 'Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902', Radiotherapy and Oncology. https://doi.org/10.1016/j.radonc.2019.08.020
Hamstra, Daniel A. ; Pugh, Stephanie L. ; Lepor, Herbert ; Rosenthal, Seth A. ; Pienta, Kenneth ; Gomella, Leonard ; Peters, Christopher ; D'Souza, David Paul ; Zeitzer, Kenneth L. ; Jones, Christopher U. ; Hall, William A. ; Horwitz, Eric ; Pisansky, Thomas M. ; Souhami, Luis ; Hartford, Alan C. ; Dominello, Michael ; Feng, Felix ; Sandler, Howard M. / Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation : An analysis of RTOG 9202 and 9902. In: Radiotherapy and Oncology. 2019.
@article{ea6be73c2e7d49c2ab795973f2351f80,
title = "Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902",
abstract = "Background/purpose: Stratification of Gleason score (GS) into three categories (2–6, 7, and 8–10) may not fully utilize its prognostic discrimination, with Gleason pattern 5 (GP5) previously identified as an independent adverse factor. Materials/methods: Patients treated on RTOG 9202 (n = 1292) or RTOG 9902 (n = 378) were pooled and assessed for association of GS and GP5 on biochemical failure (BF), local failure (LF), distant metastasis (DM), and overall survival (OS). Fine and Gray's regression and cumulative incidence methods were used for univariate and multivariate analyses. Results: With median follow-up of 9.4 years, patients with GS 8–10 with GP5 had worse outcome than GS 4 + 4 for DM on both RTOG9202 (p = 0.038) and RTOG9902 (p < 0.001) with a trend toward worse OS (p = 0.059 and p = 0.089, respectively), but without differences in BF or LF. At 10-years DM was higher by 11{\%} (RTOG 9202) and 18{\%} (RTOG 9902) with GP5 compared to GS 4 + 4. On multivariate analysis restricted to long-term androgen deprivation therapy the presence of GP5 substantially increased distant metastasis (HR = 0.43, 95{\%}CI: 0.24–0.76, p = 0.0039) with a trend toward worse OS (HR:0.74, 95{\%} CI:0.54–1.0, p = 0.052) without association with LF (HR:0.55, 95{\%}CI:0.28–1.09, p = 0.085) or BF (HR:1.15, 95{\%}CI:0.84–1.59, p = 0.39). We did not observed substantial differences between Gleason 3 + 5, 5 + 3, or Gleason 9–10. Conclusions: These results validate GP5 as an independent prognostic factor which is strongest for DM. As a result GP5 should be considered when stratifying patients with GS 8 and may be a patient population in which to evaluate newly approved systemic therapies or additional local treatments.",
keywords = "Distant metastasis, Gleason score, Prostate cancer, Radiation therapy",
author = "Hamstra, {Daniel A.} and Pugh, {Stephanie L.} and Herbert Lepor and Rosenthal, {Seth A.} and Kenneth Pienta and Leonard Gomella and Christopher Peters and D'Souza, {David Paul} and Zeitzer, {Kenneth L.} and Jones, {Christopher U.} and Hall, {William A.} and Eric Horwitz and Pisansky, {Thomas M.} and Luis Souhami and Hartford, {Alan C.} and Michael Dominello and Felix Feng and Sandler, {Howard M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.radonc.2019.08.020",
language = "English (US)",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation

T2 - An analysis of RTOG 9202 and 9902

AU - Hamstra, Daniel A.

AU - Pugh, Stephanie L.

AU - Lepor, Herbert

AU - Rosenthal, Seth A.

AU - Pienta, Kenneth

AU - Gomella, Leonard

AU - Peters, Christopher

AU - D'Souza, David Paul

AU - Zeitzer, Kenneth L.

AU - Jones, Christopher U.

AU - Hall, William A.

AU - Horwitz, Eric

AU - Pisansky, Thomas M.

AU - Souhami, Luis

AU - Hartford, Alan C.

AU - Dominello, Michael

AU - Feng, Felix

AU - Sandler, Howard M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/purpose: Stratification of Gleason score (GS) into three categories (2–6, 7, and 8–10) may not fully utilize its prognostic discrimination, with Gleason pattern 5 (GP5) previously identified as an independent adverse factor. Materials/methods: Patients treated on RTOG 9202 (n = 1292) or RTOG 9902 (n = 378) were pooled and assessed for association of GS and GP5 on biochemical failure (BF), local failure (LF), distant metastasis (DM), and overall survival (OS). Fine and Gray's regression and cumulative incidence methods were used for univariate and multivariate analyses. Results: With median follow-up of 9.4 years, patients with GS 8–10 with GP5 had worse outcome than GS 4 + 4 for DM on both RTOG9202 (p = 0.038) and RTOG9902 (p < 0.001) with a trend toward worse OS (p = 0.059 and p = 0.089, respectively), but without differences in BF or LF. At 10-years DM was higher by 11% (RTOG 9202) and 18% (RTOG 9902) with GP5 compared to GS 4 + 4. On multivariate analysis restricted to long-term androgen deprivation therapy the presence of GP5 substantially increased distant metastasis (HR = 0.43, 95%CI: 0.24–0.76, p = 0.0039) with a trend toward worse OS (HR:0.74, 95% CI:0.54–1.0, p = 0.052) without association with LF (HR:0.55, 95%CI:0.28–1.09, p = 0.085) or BF (HR:1.15, 95%CI:0.84–1.59, p = 0.39). We did not observed substantial differences between Gleason 3 + 5, 5 + 3, or Gleason 9–10. Conclusions: These results validate GP5 as an independent prognostic factor which is strongest for DM. As a result GP5 should be considered when stratifying patients with GS 8 and may be a patient population in which to evaluate newly approved systemic therapies or additional local treatments.

AB - Background/purpose: Stratification of Gleason score (GS) into three categories (2–6, 7, and 8–10) may not fully utilize its prognostic discrimination, with Gleason pattern 5 (GP5) previously identified as an independent adverse factor. Materials/methods: Patients treated on RTOG 9202 (n = 1292) or RTOG 9902 (n = 378) were pooled and assessed for association of GS and GP5 on biochemical failure (BF), local failure (LF), distant metastasis (DM), and overall survival (OS). Fine and Gray's regression and cumulative incidence methods were used for univariate and multivariate analyses. Results: With median follow-up of 9.4 years, patients with GS 8–10 with GP5 had worse outcome than GS 4 + 4 for DM on both RTOG9202 (p = 0.038) and RTOG9902 (p < 0.001) with a trend toward worse OS (p = 0.059 and p = 0.089, respectively), but without differences in BF or LF. At 10-years DM was higher by 11% (RTOG 9202) and 18% (RTOG 9902) with GP5 compared to GS 4 + 4. On multivariate analysis restricted to long-term androgen deprivation therapy the presence of GP5 substantially increased distant metastasis (HR = 0.43, 95%CI: 0.24–0.76, p = 0.0039) with a trend toward worse OS (HR:0.74, 95% CI:0.54–1.0, p = 0.052) without association with LF (HR:0.55, 95%CI:0.28–1.09, p = 0.085) or BF (HR:1.15, 95%CI:0.84–1.59, p = 0.39). We did not observed substantial differences between Gleason 3 + 5, 5 + 3, or Gleason 9–10. Conclusions: These results validate GP5 as an independent prognostic factor which is strongest for DM. As a result GP5 should be considered when stratifying patients with GS 8 and may be a patient population in which to evaluate newly approved systemic therapies or additional local treatments.

KW - Distant metastasis

KW - Gleason score

KW - Prostate cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85072167922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072167922&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2019.08.020

DO - 10.1016/j.radonc.2019.08.020

M3 - Article

C2 - 31540746

AN - SCOPUS:85072167922

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -